Octreotide clinical trials
Also written Sandostatin, SMS995 and MYCAPSSA™.
Includes 5 studies of Octreotide hydrochloride and 2 studies of Octreotide pamoate.
How each study uses Octreotide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Octreotide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Oct 1988 · SANDOSTATIN · NDA 019667 (FDA, Drugs@FDA)
- European Union
- 2 Dec 2022 · Mycapssa · EMEA/H/C/005826 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
117 studies that test it; most in 2005 (10); 1 more planned to start later
| Year | Studies |
|---|---|
| 1995 | 2 |
| 1996 | 2 |
| 1997 | 2 |
| 1998 | 2 |
| 1999 | 3 |
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 8 |
| 2003 | 7 |
| 2004 | 4 |
| 2005 | 10 |
| 2006 | 6 |
| 2007 | 5 |
| 2008 | 6 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 4 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 41 · Other 80
Novartis Pharmaceuticals (13) · Novartis (7) · Camurus AB (5) · Endo Pharmaceuticals (4) · Columbia University (3) · Eastern Cooperative Oncology Group (3) · Chiasma, Inc. (3) · Alliance for Clinical Trials in Oncology (3)
Often tested with
Tested in the same studies.
Midodrine (7) · Octreotide Depot Formulation CAM2029 (5) · Glucose (3) · Everolimus (3) · Terlipressin (3) · Pegvisomant (3) · Acetazolamide (2) · Atomoxetine (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Octreotide is the comparator. A study of two new drugs counts under both.
- 1Actinium AC-225 dotatate · RayzeBio, Inc. · next primary completion Dec 2026
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Octreotide, phase 3 first.
- Nov 2026A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETPhase 3 · Camurus AB
Studies
Open first, then newest update. How each study uses Octreotide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 121
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With AcromegalyNot yet recruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07623824Written as Sandostatin LAR®
- Human Models of Selective Insulin Resistance: Pancreatic ClampNot yet recruitingPhase 1Columbia UniversityNCT06558422Written as Octreotide Acetate
- Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)Not yet recruitingPhase 4King Faisal Specialist Hospital & Research CenterNCT06974344Written as Octreotide (drug)
- Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.RecruitingPhase 2Clinica Universidad de Navarra, Universidad de NavarraNCT06085976Written as Octreotide
- Role of Octreotide in Non Variceal BleedingRecruitingPhase 2/3National Hepatology & Tropical Medicine Research InstituteNCT06062719Written as PPI plus octreotide
- Treatment of Orthostatic IntoleranceActive, not recruitingPhase 1/2Satish R. RajNCT00262470Written as Octreotide
- Intranasal Delivery of Octreotide for Treatment of Diabetic Macular EdemaWithdrawnPhase 1University of Alabama at BirminghamNCT06881888Written as Octreotide (drug)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyCompletedPhase 3Camurus ABNCT04076462Written as CAM2029 (octreotide subcutaneous depot)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETActive, not recruitingPhase 3Camurus ABNCT05050942Written as CAM2029
- A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLDActive, not recruitingPhase 2/3Camurus ABNCT05281328Written as CAM2029
- Pancreatic Clamp in NAFLDCompletedPhase 1Columbia UniversityNCT05724134Written as Octreotide Acetate
- A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyCompletedPhase 3Camurus ABNCT04125836Written as CAM2029 (octreotide subcutaneous depot)
- Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal VaricesTerminatedPhase 4Medical University of South CarolinaNCT03624517Written as Octreotide
- A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus LanreotideCompletedPhase 4Memorial Sloan Kettering Cancer CenterNCT03289741Written as Octreotide
- Treatment of Idiopathic Pulmonary Fibrosis with Long Acting OctreotideCompletedPhase 1/2Institut National de la Santé Et de la Recherche Médicale, FranceNCT00463983Written as octreotide
- Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric CancerCompletedPhase 2Fredrik KlevebroNCT04871204Written as Octreotide Injection
- Effects of Sandostatin LAR® in AcromegalyCompletedPhase 4Columbia UniversityNCT01424241Written as Sandostatin LAR
- Trial Using Octreotide to Enhance Liver Recovery After HepatectomyTerminatedPhase 2Fox Chase Cancer CenterNCT03179995Written as Octreotide
- Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for CancerCompletedNot applicableSt. James's Hospital, IrelandNCT02385617Written as Octreotide
- The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal SurgeryCompletedNot applicableSt. James's Hospital, IrelandNCT02381249Written as Octreotide
See all 121 studies that test Octreotide →
Given beside what is tested · 32 — Octreotide is usual care or a partner of the new treatment
- Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETRecruitingPhase 3Novartis PharmaceuticalsNCT06784752Written as Octreotide LAR
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine TumorActive, not recruitingPhase 3National Cancer Institute (NCI)NCT00569127Written as Octreotide Acetate
- RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine CarcinomaCompletedPhase 2M.D. Anderson Cancer CenterNCT00113360Written as Octreotide Depot
- Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine CarcinomasCompletedPhase 2/3Grupo Espanol de Tumores NeuroendocrinosNCT01744249Written as Sandostatin LAR
- Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine TumorsCompletedPhase 1Roswell Park Cancer InstituteNCT03879694Written as Octreotide Acetate
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETActive, not recruitingPhase 3Advanced Accelerator ApplicationsNCT03972488Written as 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)
- Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical CarcinomasTerminatedPhase 2National Cancer Institute (NCI)NCT06865677Written as Octreotide
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)TerminatedPhase 1Debiopharm International SANCT05364944Written as Sandostatin LAR
- Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomyCompletedPhase 3University of LiverpoolNCT02457156Written as Octreotide
- Dexamethasone/Pancreatic Clamp P&FWithdrawnPhase 1Columbia UniversityNCT06126354Written as Octreotide Acetate
- AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsCompletedPhase 2Eastern Cooperative Oncology GroupNCT00427349Written as octreotide
- Acromegaly Combination Treatment StudyTerminatedNot applicableCedars-Sinai Medical CenterNCT01538966Written as Octreotide LAR
- A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursCompletedPhase 3Advanced Accelerator ApplicationsNCT01578239Written as Octreotide LAR
- Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.CompletedPhase 4Novartis PharmaceuticalsNCT01789281Written as Sandostatin LAR Depot
- A Study of Cixutumumab (IMC-A12) in Islet Cell CancerCompletedPhase 2Eli Lilly and CompanyNCT00781911Written as depot octreotide
- Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast CancerTerminatedPhase 2Novartis PharmaceuticalsNCT02294786Written as Octreotide
- A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid TumorsWithdrawnPhase 1Massachusetts General HospitalNCT03057509Written as LAR Octreotide
- Effects of Glucagon Administration on Energy ExpenditureCompletedPhase 1AdventHealth Translational Research InstituteNCT02237053Written as Octreotide
- The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated AcromegalicsCompletedPhase 2Aspireo Pharmaceuticals LimitedNCT02217800Written as octreotide
- Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.CompletedPhase 2Aspireo Pharmaceuticals LimitedNCT02235987Written as octreotide
Showing 20 of 32.
As the comparator · 14 — what is tested is compared with Octreotide
- A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETsCompletedPhase 3Sinotau Pharmaceutical GroupNCT05459844Written as Octreotide LAR
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingPhase 3RayzeBio, Inc.NCT05477576Written as Octreotide
- A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)CompletedPhase 1Triastek (Shanghai) LimitedNCT07663318Written as Mycapssa
- A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With AcromegalyCompletedPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07814651Written as Sandostatin LAR
- Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal SyndromeCompletedNot applicableLahore General HospitalNCT07460908Written as Octreotide (drug)
- Prevention of Postoperative Pancreatic Fistula by SomatostatinCompletedPhase 3Assistance Publique - Hôpitaux de ParisNCT03000946Written as Octreotide
- Angiotensin 2 for Hepatorenal SyndromeWithdrawnPhase 2University of California, Los AngelesNCT04048707Written as Octreotide
- Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®SuspendedPhase 1Azidus BrasilNCT01086982Written as Sandostatin LAR ® (octreotide acetate LAR) 30 MG
- Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)Status unknownPhase 4Nanfang Hospital, Southern Medical UniversityNCT04028323Written as Octreotide
- A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult VolunteersTerminatedPhase 1Ono Pharmaceutical Co. LtdNCT03571594Written as Octreotide
- Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active AcromegalyCompletedPhase 3Novartis PharmaceuticalsNCT00600886Written as Octreotide
- Phase II Study With ITF2984 in Acromegalic PatientsCompletedPhase 2ItalfarmacoNCT02111044Written as Octreotide
- Hemodynamic Effects of Terlipressin and High Dose OctreotideCompletedPhase 4Shanghai Zhongshan HospitalNCT02119884Written as Octreotide
- ITF2984 Repeated Doses Study in Healthy VolunteersCompletedPhase 1ItalfarmacoNCT01871844Written as octreotide 50 mcg tid
Codes
What other systems call Octreotide · ClinicalTrials.gg INT008456
- MeSH (NLM) D015282OctreotideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) RWM8CCW8GPOCTREOTIDEConfirmed FDA, NLM, Wikidata
- RxNorm 7617Confirmed FDA, Wikidata
- Wikidata Q419935octreotideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C711OctreotideConfirmed FDA, Wikidata
- DrugBank DB00104One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D015282 | Octreotide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | RWM8CCW8GP | OCTREOTIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 7617 | — | Confirmed FDA, Wikidata |
| Wikidata | Q419935 | octreotide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C711 | Octreotide | Confirmed FDA, Wikidata |
| DrugBank | DB00104 | — | One source Wikidata |
Also registered as octreotide acetate (UNII 75R0U2568I · RxNorm 221130).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.